AU2018208516B2 - Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof - Google Patents

Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof Download PDF

Info

Publication number
AU2018208516B2
AU2018208516B2 AU2018208516A AU2018208516A AU2018208516B2 AU 2018208516 B2 AU2018208516 B2 AU 2018208516B2 AU 2018208516 A AU2018208516 A AU 2018208516A AU 2018208516 A AU2018208516 A AU 2018208516A AU 2018208516 B2 AU2018208516 B2 AU 2018208516B2
Authority
AU
Australia
Prior art keywords
acetonitrile
trans
disease
compound
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018208516A
Other languages
English (en)
Other versions
AU2018208516A1 (en
Inventor
Tine Marianne DUUS
Jens Larsen
Mogens Larsen
Lars Kyhn Rasmussen
Andreas Ritzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqilion AB
Original Assignee
Aqilion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion AB filed Critical Aqilion AB
Publication of AU2018208516A1 publication Critical patent/AU2018208516A1/en
Application granted granted Critical
Publication of AU2018208516B2 publication Critical patent/AU2018208516B2/en
Assigned to AQILION AB reassignment AQILION AB Request for Assignment Assignors: LEO PHARMA A/S
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018208516A 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof Active AU2018208516B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
EP17151020.9 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
AU2018208516A1 AU2018208516A1 (en) 2019-07-11
AU2018208516B2 true AU2018208516B2 (en) 2021-07-08

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018208516A Active AU2018208516B2 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof

Country Status (25)

Country Link
US (1) US10703751B2 (enExample)
EP (1) EP3568396B1 (enExample)
JP (1) JP7009504B2 (enExample)
KR (1) KR102548543B1 (enExample)
CN (1) CN110167938B (enExample)
AU (1) AU2018208516B2 (enExample)
CA (1) CA3045567A1 (enExample)
CY (1) CY1123864T1 (enExample)
DK (1) DK3568396T3 (enExample)
ES (1) ES2846741T3 (enExample)
HR (1) HRP20210095T1 (enExample)
HU (1) HUE052720T2 (enExample)
IL (1) IL267829B (enExample)
LT (1) LT3568396T (enExample)
MX (1) MX389378B (enExample)
MY (1) MY195576A (enExample)
PL (1) PL3568396T3 (enExample)
PT (1) PT3568396T (enExample)
RS (1) RS61317B1 (enExample)
RU (1) RU2019125177A (enExample)
SI (1) SI3568396T1 (enExample)
TW (1) TWI760419B (enExample)
UA (1) UA123972C2 (enExample)
WO (1) WO2018130563A1 (enExample)
ZA (1) ZA201904190B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP7345220B2 (ja) * 2019-08-30 2023-09-15 ティーエスディー ライフ サイエンス カンパニー リミテッド イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011086053A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
SG10201505997TA (en) * 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
UY34616A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3181564B1 (en) * 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
EA201990523A1 (ru) 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011086053A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors

Also Published As

Publication number Publication date
NZ754922A (en) 2025-11-28
CA3045567A1 (en) 2018-07-19
JP2020504186A (ja) 2020-02-06
TWI760419B (zh) 2022-04-11
CN110167938A (zh) 2019-08-23
BR112019014191A2 (pt) 2020-02-11
IL267829A (en) 2019-09-26
HRP20210095T1 (hr) 2021-03-05
MX389378B (es) 2025-03-20
RU2019125177A (ru) 2021-02-15
ES2846741T3 (es) 2021-07-29
MY195576A (en) 2023-02-02
PL3568396T3 (pl) 2021-05-31
US20190367512A1 (en) 2019-12-05
DK3568396T3 (da) 2021-01-18
WO2018130563A1 (en) 2018-07-19
EP3568396A1 (en) 2019-11-20
KR102548543B1 (ko) 2023-06-29
PT3568396T (pt) 2021-02-09
LT3568396T (lt) 2021-02-10
CY1123864T1 (el) 2022-05-27
TW201829407A (zh) 2018-08-16
IL267829B (en) 2022-02-01
US10703751B2 (en) 2020-07-07
EP3568396B1 (en) 2020-11-11
ZA201904190B (en) 2020-10-28
RU2019125177A3 (enExample) 2021-05-11
KR20190103231A (ko) 2019-09-04
SI3568396T1 (sl) 2021-04-30
RS61317B1 (sr) 2021-02-26
HUE052720T2 (hu) 2021-05-28
JP7009504B2 (ja) 2022-01-25
AU2018208516A1 (en) 2019-07-11
CN110167938B (zh) 2024-06-14
MX2019008331A (es) 2020-01-14
UA123972C2 (uk) 2021-06-30

Similar Documents

Publication Publication Date Title
US10703751B2 (en) Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
EP3939979A1 (en) Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
TW201309703A (zh) 作為蛋白質酪胺酸激酶抑制劑之新穎磺醯胺哌□衍生物及其醫藥用途
EP3576743B1 (en) 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors
EP4261211A1 (en) Dihydroisoquinolinone derivative and application thereof
EP3954680A1 (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
EP3818060B1 (en) Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
CN105102435A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
BR112019014191B1 (pt) Composto e composição farmacêutica
HK40013317A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
EP4698531A1 (en) Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
HK40013317B (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
WO2022117012A1 (zh) 螺环jak抑制剂、含其的药物组合物及其应用
KR20250121126A (ko) Irak3의 리간드 지정 분해제로서의 치환된 이미다조-기재 화합물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AQILION AB

Free format text: FORMER OWNER(S): LEO PHARMA A/S